as 05-17-2024 3:31pm EST
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Founded: | 2014 | Country: | China |
Employees: | N/A | City: | N/A |
Market Cap: | 82.1M | IPO Year: | 2020 |
Target Price: | N/A | AVG Volume (30 days): | 4.9K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -8.83 | EPS Growth: | N/A |
52 Week Low/High: | $5.72 - $29.20 | Next Earning Date: | 05-28-2024 |
Revenue: | $75,801,834 | Revenue Growth: | -4.58% |
Revenue Growth (this year): | 52.9% | Revenue Growth (next year): | 48.35% |
BNR Breaking Stock News: Dive into BNR Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
GlobeNewswire
19 days ago
GlobeNewswire
22 days ago
Thomson Reuters StreetEvents
2 months ago
GlobeNewswire
2 months ago
Simply Wall St.
4 months ago
GlobeNewswire
4 months ago
Simply Wall St.
4 months ago